Pharmamarketeer
onderzoek

Novartis phase III ASCLEPIOS I & II studies of ofatumumab versus Aubagio to treat relapsing forms MS meets primary endpoints

2 september 2019
Pharma Biz

Novartis announced positive results for ofatumumab (OMB157) from the phase III ASCLEPIOS I and II studies. In both head─to─head studies, ofatumumab demonstrated superiority over Aubagio (teriflunomide) in patients

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)